证券代码：003020 证券简称：立方制药 公告编号：2025-076 合肥立方制药股份有限公司 关于收到药品注册受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，合肥立方制药股份有限公司（以下简称"公司"或"立方制药"）收到 国家药品监督管理局下发的达格列净二甲双胍缓释片（I）、达格列净二甲双胍缓释 片（II）及达格列净二甲双胍缓释片（III）药品注册上市许可申请《受理通知书》。 现将相关情况公告如下： 一、《受理通知书》主要内容 申请事项：境内生产药品注册上市许可 三、对公司的影响及风险提示 达格列净二甲双胍缓释片注册上市许可申请获得受理，表示该品种进入注册审 1 评阶段，对公司短期业绩不会产生重大影响。如该品种顺利通过注册审评，将进一 步丰富公司产品线，提升公司市场竞争力。由于相关产品的注册批准文件取得时间 和结果均具有不确定性，敬请广大投资者谨慎决策，注意投资风险。 特此公告。 合肥立方制药股份有限公司 董事会 2025年11月22日 | 产品名称 | 规格 | 受理号 | | --- | --- | --- | | 达格列净二甲 ...

Meeting Overview - The second extraordinary general meeting of Hefei Lifan Pharmaceutical Co., Ltd. was held on November 17, 2025, with a combination of on-site and online voting methods [3][8] - The meeting was convened by the company's board of directors and presided over by Chairman Ji Junqiu [4][5] Attendance and Voting - A total of 189 shareholders and their proxies attended the meeting, representing 120,229,876 shares, which is 63.2183% of the total voting shares [6] - Among them, 13 shareholders attended the meeting on-site, representing 106,381,385 shares (55.9366%), while 175 shareholders participated via online voting, representing 13,848,491 shares (7.2817%) [6] - Small and medium-sized shareholders accounted for 16,452,031 shares (8.6507%) of the total voting shares [7] Resolutions and Legal Compliance - No proposals were rejected during the meeting, and it did not involve changes to previously approved resolutions [8] - The meeting's procedures were confirmed to comply with the Company Law of the People's Republic of China and the company's articles of association, as verified by the witnessing lawyers [9] Documentation - The resolutions from the meeting and the legal opinion from Beijing Jingtian & Gongcheng Law Firm are available for review [10]

证券代码：003020 证券简称：立方制药 公告编号：2025-074 合肥立方制药股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决提案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、召开时间 （1）现场会议召开时间：2025 年 11 月 17 日（星期一）下午 15:00； 2、现场会议召开地点：安徽省合肥市文曲路 446 号科研综合楼五楼会议中 心。 （2）网络投票时间： 通过深圳证券交易所交易系统投票的时间为：2025 年 11 月 17 日 9:15—9:25、 9:30—11:30、下午 13:00—15:00； 通过深圳证券交易所互联网投票系统投票的时间为：2025 年 11 月 17 日 9:15 —15:00。 3、会议召开方式：现场投票与网络投票相结合的方式。 4、会议召集人：公司董事会。 5、会议主持人：公司董事长季俊虬先生。 6、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规、规范性文件 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 关于合肥立方制药股份有限公司 2025年第二次临时股东会的法律意见书 致：合肥立方制药股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受合肥立方制药股份有限 公司（以下简称"公司"）的委托，指派本所律师列席公司于 2025 年 11 月 17 日 下午 15 时在安徽省合肥市文曲路 446 号科研综合楼五楼会议中心召开的 2025 年第二次临时股东会（以下称"本次股东会"），并依据《中华人民共和国公司法》 等中国法律、法规和相关规范性文件（以下称"中国法律法规"）及《合肥立方制 药股份有限公司章程》（以下称"公司章程"）的规定，就本次股东会的召集和召 开程序、出席会议人员资格、召集人资格、会议表决程序和表决结果等事宜（以 下称"程序事宜"）出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的有关本次股东会的文件， 包括但不限于公司第六届董事会第二次会议决议以及根据上述决议内容刊登的 公告、本次股东会的通知、议案 ...

Core Viewpoint - Aipeng Medical and Cube Pharmaceutical signed a strategic cooperation framework agreement to establish a joint innovation center focusing on rapid response mechanisms for clinical needs, technology research and development, and achievement transformation [1] Group 1: Strategic Cooperation - The partnership aims to conduct joint research on AI, brain-computer interfaces, and drug efficacy evaluation [1] - The collaboration will promote coordinated clinical research between medical devices and pharmaceuticals [1] Group 2: Academic and Social Engagement - Both companies will collaborate with academic institutions and industry associations to facilitate scientific exchanges and public awareness activities [1] - The initiative aims to enhance standardized diagnosis and treatment of ADHD and improve social recognition [1]

Group 1 - The core viewpoint of the news is that Lifan Pharmaceutical's stock has increased by 5.37%, reaching a price of 28.46 CNY per share, with a total market capitalization of 5.413 billion CNY as of the report date [1] - Lifan Pharmaceutical, established on July 16, 2002, and listed on December 15, 2020, is primarily engaged in the research, production, and sales of pharmaceutical formulations and raw materials, with 97.50% of its revenue coming from pharmaceutical products [1] - The company has a trading volume of 91.038 million CNY and a turnover rate of 2.38% [1] Group 2 - In the context of major shareholders, Invesco Great Wall Fund's healthcare mixed fund has entered the top ten circulating shareholders of Lifan Pharmaceutical, holding 910,100 shares, which is 0.66% of the circulating shares [2] - The Invesco Great Wall Healthcare Mixed A Fund (011876) has achieved a year-to-date return of 28.64% and a one-year return of 24.58%, ranking 3331 out of 8154 and 3709 out of 8046 in its category, respectively [2] - The fund was established on August 18, 2021, and has a current scale of 368 million CNY, with an estimated floating profit of approximately 1.3196 million CNY from its investment in Lifan Pharmaceutical [2]

Core Insights - Cube Pharmaceuticals (003020.SZ) reported its Q3 2025 results on October 30, 2025, highlighting a total of 39.4014 million A-shares held by three institutional investors, representing 20.72% of the company's total share capital [1] Institutional Holdings - The institutional investors include Hefei Cube Investment Group Co., Ltd., China Merchants Fund Management Co., Ltd. - Social Security Fund 2108 Portfolio, and China Minsheng Bank Co., Ltd. - Invesco Great Wall Medical Health Mixed Securities Investment Fund [1] - Compared to the previous quarter, the total institutional holding percentage decreased by 0.06 percentage points [1] Public Fund Activity - One new public fund disclosed its holdings in Cube Pharmaceuticals this quarter, specifically Invesco Great Wall Medical Health Mixed Class A [1] - A total of 60 public funds were not disclosed in this quarter compared to the previous one, including Hai Fu Tong Growth Value Mixed A, CITIC Construction Investment Rotation Mixed A, and others [1] Social Security Fund - One new social security fund disclosed its holdings in Cube Pharmaceuticals, which is the China Merchants Fund Management Co., Ltd. - Social Security Fund 2108 Portfolio [1]

Core Viewpoint - Lifan Pharmaceutical (003020.SZ) reported a decline in revenue for the first three quarters of 2025, while net profit showed a slight increase, indicating mixed financial performance [1] Financial Performance - The company achieved an operating revenue of 1.081 billion yuan, a year-on-year decrease of 3.95% [1] - The net profit attributable to shareholders of the listed company was 121 million yuan, reflecting a year-on-year increase of 1.65% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 89.35 million yuan, which represents a year-on-year decrease of 20.23% [1] - Basic earnings per share stood at 0.64 yuan [1]

Core Viewpoint - The company reported a decline in revenue for the first three quarters of 2025, while net profit showed a slight increase, indicating mixed financial performance [1] Financial Performance - The company achieved operating revenue of 1.081 billion yuan for the first three quarters, representing a year-on-year decrease of 3.95% [1] - The net profit attributable to shareholders of the listed company was 121 million yuan, reflecting a year-on-year increase of 1.65% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 89.35 million yuan, which is a year-on-year decrease of 20.23% [1]

Company Overview - Lifan Pharmaceutical (SZ 003020) announced the convening of its sixth second board meeting on October 28, 2025, to review the proposal for the "2025 Third Quarter Report" [1] - As of the report, Lifan Pharmaceutical has a market capitalization of 5.4 billion yuan [1] Revenue Composition - For the first half of 2025, Lifan Pharmaceutical's revenue composition is as follows: - Pharmaceutical manufacturing accounted for 91.14% - Pharmaceutical retail accounted for 7.71% - Other segments accounted for 1.16% [1]